Cargando…

Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

As part of its single technology appraisal process, the National Institute for Health and Care Excellence invited the manufacturer (Eli Lilly) of baricitinib (BARI; Olumiant(®); a Janus kinase inhibitor that is taken orally) to submit evidence of its clinical and cost effectiveness for the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Shijie, Bermejo, Iñigo, Simpson, Emma, Wong, Ruth, Scott, David L., Young, Adam, Stevenson, Matt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999127/ https://www.ncbi.nlm.nih.gov/pubmed/29502174 http://dx.doi.org/10.1007/s40273-018-0616-7

Ejemplares similares

Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals
por: Kiely, Patrick D. W., et al.
Publicado: (2012)

Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2021)

Baricitinib for the treatment of rheumatoid arthritis
por: Urits, Ivan, et al.
Publicado: (2020)

The impact of rarity in NICE’s health technology appraisals
por: Clarke, Sophie, et al.
Publicado: (2021)

Baricitinib exposure during pregnancy in rheumatoid arthritis
por: Costanzo, Giulia, et al.
Publicado: (2020)

Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
por: Hashem, Ferhana, et al.
Publicado: (2017)

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
por: Schlueter, Max, et al.
Publicado: (2019)

Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
por: Li, SiNi, et al.
Publicado: (2021)

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
por: Taylor, Peter C., et al.
Publicado: (2019)

Management of rheumatoid arthritis: summary of NICE guidance
por: Deighton, Chris, et al.
Publicado: (2009)

Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis
por: Hushaw, Linda L, et al.
Publicado: (2010)

Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2017)

Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2021)

NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias
por: Brown, Patrick, et al.
Publicado: (2011)

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
por: Kawalec, Paweł, et al.
Publicado: (2019)

Are There Any Ethnic Differences in the Response to Baricitinib for the Treatment of Rheumatoid Arthritis?
por: Zahir Hussain, Wajith Hussain, et al.
Publicado: (2021)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2018)

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties
por: Dickson, Rumona, et al.
Publicado: (2018)

The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis
por: Thudium, Christian S., et al.
Publicado: (2020)

Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2022)

Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
por: Latimer, Nicholas R., et al.
Publicado: (2014)

Audit of data redaction practices in NICE technology appraisals from 1999 to 2019
por: Osipenko, Leeza
Publicado: (2021)

Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: van Asselt, Antoinette D. I., et al.
Publicado: (2023)

Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis
por: Koumaki, Dimitra, et al.
Publicado: (2019)

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2020)

Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Witlox, Willem J. A., et al.
Publicado: (2020)

Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease
por: Taylor, Peter C., et al.
Publicado: (2023)

A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process
por: Kaltenthaler, Eva C, et al.
Publicado: (2012)

It’s not evidence, it’s insight: bringing patients’ perspectives into health technology appraisal at NICE
por: Staley, Kristina, et al.
Publicado: (2016)

Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
por: Büyükkaramikli, Nasuh C., et al.
Publicado: (2017)

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study
por: Smolen, Josef S, et al.
Publicado: (2020)

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
por: Genovese, Mark C, et al.
Publicado: (2018)

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
por: Iwamoto, Naoki, et al.
Publicado: (2021)

Effectiveness of Baricitinib in Refractory Seronegative Rheumatoid Arthritis and Uveitis: A Case Report
por: Kaneko, Yutaka, et al.
Publicado: (2022)

Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis
por: Hernández-Cruz, Blanca, et al.
Publicado: (2023)

Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Mistry, Hema, et al.
Publicado: (2017)

Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis
por: Hale, George, et al.
Publicado: (2023)

A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process
por: Walton, M. J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0sv1c7peklci4l21sbl9j2f97e